Why the study?
Do angiotensin receptor blockers improve cardioprotective and renoprotective outcomes compared to angiotensin-converting enzyme inhibitors in high-risk patients?
Population
High-risk patients with or without heart failure, hypertension, and associated vascular disorders
Comparison
Angiotensin receptor blockers (ARBs) vs Angiotensin-converting enzyme inhibitors (ACEIs)
Design
Review
Authors
Loading...
ARBs may offer alternatives for ACEI-intolerant high-risk patients; leaves open whether they confer superior cardioprotection versus ACEIs.
Do angiotensin receptor blockers improve cardioprotective and renoprotective outcomes compared to angiotensin-converting enzyme inhibitors in high-risk patients?
ARBs offer a valuable, well-tolerated alternative to ACE inhibitors for cardioprotection and renoprotection in high-risk patients.
Basile et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: